Botox USA vs Korea is mostly a question of which product label goes into the syringe, because the active drug in both countries is botulinum toxin type A. Allergan's Botox and Merz's Xeomin are licensed in the US and in Korea, Daewoong's Nabota is sold in the US under the name Jeuveau, and Korean menus add several domestic brands that American offices do not carry. Published trials let you compare some of these products directly rather than by reputation. This page walks through which labels each regulator covers, what a Korean head-to-head trial against onabotulinumtoxinA found, what two years of repeat dosing showed, and the gaps that matter when one treatment happens in Haeundae and the next one back home.
Guide
Which toxin labels each regulator covers
The US Food and Drug Administration and Korea's Ministry of Food and Drug Safety license products separately. A brand that is routine in a Busan clinic may never have been submitted in the US, and the reverse is also possible. The molecule class does not change, but the manufacturing process, the added proteins and the potency test behind a unit all belong to one manufacturer.
Korean clinics usually sort their menu into imported originals, purified imported products and Korean-made brands. Coretox from Medytox, for example, is a Korean formula purified down to the 150 kDa neurotoxin without human serum albumin. Before assuming your home injector knows a product, ask for its exact brand and check its label status where you live.
| Product | Maker | Generic name | US status | Korea status |
|---|---|---|---|---|
| Botox | Allergan (AbbVie), US | onabotulinumtoxinA | FDA approved | Imported and licensed |
| Xeomin | Merz, Germany | incobotulinumtoxinA | FDA approved in 2011 | Licensed for frown lines |
| Nabota | Daewoong, Korea | prabotulinumtoxinA | Sold as Jeuveau since 2019 | Licensed |
| Innotox | Medytox, Korea | Ready-mixed liquid toxin type A | Not FDA approved | Licensed in Korea only |
Guide
What a Korean trial against onabotulinumtoxinA measured
A 2020 Phase I/III study by Han and colleagues in Dermatologic Surgery tested HU-014, a Korean-developed botulinum toxin type A, against onabotulinumtoxinA for crow's feet. In the Phase III part, 290 adults with moderate to severe lines were randomized one to one, given a single treatment and followed for 16 weeks under double-blind conditions.
The main endpoint was a near-flat line on maximum smile at week four. Seventy-two percent of each group reached it, which met the study's test for non-inferiority, and the two groups showed no significant differences in safety. In plain terms, the domestic product held its own against the American reference drug for this one area and this one time window.
Guide
Two years of repeat dosing with a product licensed in both countries
Rzany and colleagues reported in Dermatologic Surgery in 2013 on a two-year, open-label Phase III trial of incobotulinumtoxinA for frown lines between the brows. The paper notes the product was approved for that use in the United States and in South Korea, so it is one of the few labels a traveler can match on both sides of the Pacific.
Rzany's team followed 796 participants who received 20 units per cycle, for up to eight cycles at least 85 days apart. In that trial, 77 to 88 percent counted as responders at rest on day 30 of each cycle, and 79 to 90 percent on maximum frown. People reported an effect within the first few days, and no new safety concerns appeared. Because the study was open-label and limited to one area, it supports steady repeat use of that product rather than any ranking against other brands.
Guide
Gaps the trials leave for a cross-border patient
Neither study compared a Korean clinic with an American office. They compared products under controlled dosing, so they say nothing about technique, consultation or follow-up in either country. A single crow's feet trial and a frown line trial also do not settle how a product behaves in larger muscles, where doses are much higher.
Units are measured by each manufacturer's own potency assay, so twenty units of one brand is not automatically equal to twenty units of another. If you alternate between a Haeundae clinic and a home injector, write down the brand, total units and units per site each time. That record, not the country, is what lets the next doctor adjust the plan safely.
The effect starts over a few days and settles over roughly two weeks, so an early-trip appointment leaves room for a check in Busan before the flight from Gimhae.
Evidence
Research behind this page
- Phase I/III Clinical Trial to Evaluate the Safety and Efficacy of a New Botulinum Toxin (HU-014) Versus OnabotulinumtoxinA in Subjects With Moderate-to-Severe Crow's Feet LinesDermatologic Surgery · 2020 · doi:10.1097/dss.0000000000002807
In a randomized, double-blind trial of 290 adults with crow's feet, 72 percent in both the HU-014 and onabotulinumtoxinA groups reached the week-four endpoint, supporting non-inferiority with no significant safety differences.
- Long-Term Results for IncobotulinumtoxinA in the Treatment of Glabellar Frown LinesDermatologic Surgery · 2013 · doi:10.1111/dsu.12008
Over up to eight treatment cycles in 796 people, incobotulinumtoxinA kept producing responders for frown lines for two years, with early onset and no new safety concerns.
FAQ
Questions about Botox in Busan
Can I ask a Busan clinic for the same brand my US injector uses?
Yes, you can ask, and many clinics stock Allergan's Botox or Merz's Xeomin, which are licensed in both countries. Say the exact brand name when you request a quote and ask to see the sealed vial before it is opened. If your US office uses Jeuveau, the Korean name for the same Daewoong product is Nabota. Matching the brand keeps your unit counts comparable when you are treated again at home.
Does a non-inferiority result mean two toxins are identical?
No, it means the new product performed no worse than the reference within a set margin, for the area and time frame tested. In the 2020 Han trial, both groups reached the same week-four endpoint rate on crow's feet. The products still differ in manufacturing and unit potency. Treat the result as evidence that a Korean toxin can match the reference in that setting, not as proof that every brand behaves the same everywhere.
Do Korean clinics need FDA approval for the toxins they inject?
No, a product used in Korea needs a license from the Ministry of Food and Drug Safety, not from the US regulator. FDA approval only controls what can be marketed in the United States. That is why some Korean-made brands appear on Busan menus but not in American offices. If FDA status matters to you personally, name a product that holds it, such as Botox, Xeomin or Nabota, when you book.
Will a Korea-only brand cause trouble at my next US appointment?
Usually it simply means your home injector needs to know what you received. Bring the brand, the total units, the units per area and the date, ideally in English. A different brand can change how many units are used next time, because potency is product-specific. Leave at least the usual interval between rounds, and avoid stacking injections from two clinics close together, which makes any weakness or unevenness harder to trace.
Do the frown line trials apply to jaw or calf injections?
Only loosely, because both studies treated small facial muscles with low doses. Jaw and calf treatments use far larger amounts in thicker muscles, and the safety and response data for those areas come from separate studies. When a product is offered for a body area, ask the doctor what evidence supports that brand there. Results vary from person to person.